Position in VRTX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
5 quarters on record
Derivatives in VRTX
reported options exposure · as of Mar 31, 2026CallValue
$40,188,600
CallShares
90,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Eversept Partners, LP holds $859,319,346 across 72 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
913,880 | $121,783,648 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,212,770 | $94,949,960 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
1,785,941 | $66,454,864 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
2,798,210 | $61,168,870 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
664,684 | $52,702,794 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
798,973 | $45,389,656 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
629,952 | $36,619,109 | |
| 8 | GERN |
Geron Corp
|
18,717,422 | $23,958,300 |
All Filings in VRTX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $40,188,600 | 90,000 | Call | Sole | 2026-05-15 | |
| 2021-12-31 | $20,664,360 | 94,100 | Call | Sole | 2023-11-08 | |
| 2021-09-30 | $31,434,887 | 173,300 | Call | Sole | 2023-11-08 | |
| 2021-06-30 | $34,942,479 | 173,300 | Call | Sole | 2023-11-08 | |
| 2021-06-30 | $10,988,835 | 54,500 | Shares | Sole | 2023-11-08 | |
| 2021-03-31 | $12,893,400 | 60,000 | Call | Sole | 2023-11-08 | |
| No filing history on record for this holder in this stock. | ||||||